AfshinNDowlatiMD

Clinical Trials

• SU5416 in Treating Patients With Advanced Solid Tumors Start of enrollment: 2000 May 01

  Completed

  Phase 1

• Rebeccamycin Analogue in Treating Patients With Advanced Liver and/or Biliary Cancer Start of enrollment: 1999 Apr 01

  Terminated

  Phase 2

• Two Rebeccamycin Analogue Regimens in Treating Patients With Advanced or Recurrent Non-small Cell Lung Cancer Start of enrollment: 2000 May 01

  Completed

  Phase 2

• Temozolomide in Treating Patients With Metastatic Non-small Cell Lung Cancer Start of enrollment: 2000 Jul 01

  Completed

  Phase 2

• Imatinib Mesylate in Treating Patients With Advanced Cancer and Kidney Failure Start of enrollment: 2001 Sep 01

  Completed

  Phase 1

• Thalidomide in Treating Patients With Extensive-Stage Small Cell Lung Cancer Start of enrollment: 2002 Aug 01

  Completed

  Phase 2

• GW786034 in Treating Patients With Advanced Solid Tumors Start of enrollment: 2002 Dec 01

  Completed

  Phase 1

• Two Regimens of Docetaxel in Treating Patients Who Have Not Received Chemotherapy For Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2003 Oct 01

  Completed

  Phase 2

• Rebeccamycin Analog and Oxaliplatin in Treating Patients With Refractory Solid Tumors Start of enrollment: 2004 May 01

  Terminated

  Phase 1

• Topotecan in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer Start of enrollment: 2004 Apr 01

  Terminated

  Phase 2

• XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary Tumors Start of enrollment: 2004 Sep 01

  Terminated

  Phase 3

• Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery Start of enrollment: 2007 Jun 01

  Active, not recruiting

  Phase 3

• Bevacizumab, Cisplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer Start of enrollment: 2006 Oct 01

  Completed

  Phase 2

• Pemetrexed or Docetaxel With or Without Erlotinib in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2008 Jan 01

  Completed

  Phase 2

• Sorafenib, Cisplatin, and Etoposide in Treating Patients With Extensive-Stage Small Cell Lung Cancer Start of enrollment: 2008 Jul 01

  Terminated

  Phase 2

• Vandetanib, Oxaliplatin, and Docetaxel in Advanced Cancer of the Esophagus or Gastroesophageal Junction Start of enrollment: 2008 Oct 01

  Terminated

  Phase 1

• Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation Start of enrollment: 2009 Mar 01

  Completed

  Phase 2

• Laboratory Study Using Samples From Patients With Non-Small Cell Lung Cancer Treated on Clinical Trial CASE-2507 Start of enrollment: 2008 Aug 01

  Withdrawn

• Bevacizumab, Docetaxel, and Gemcitabine Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer Start of enrollment: 2009 Sep 01

  Completed

  Phase 2

• Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Start of enrollment: 2010 Oct 25

  Completed

  Phase 3

• Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Start of enrollment: 2011 Jun 20

  Active, not recruiting

  Phase 1

• Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction Start of enrollment: 2012 Jun 12

  Active, not recruiting

  Phase 1

• Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer Start of enrollment: 2012 Jun 01

  Completed

  Phase 2

• Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery Start of enrollment: 2013 Oct 28

  Terminated

  Phase 1

• A Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated NSCLC Start of enrollment: 2013 Sep 01

  Completed

  Phase 1

• Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction Start of enrollment: 2014 Mar 10

  Active, not recruiting

  Phase 1

• Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer Start of enrollment: 2014 Jan 01

  Completed

  Phase 1

• Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation Therapy Start of enrollment: 2015 Jun 29

  Terminated

  Phase 2

• Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer Start of enrollment: 2016 Jan 25

  Completed

  Phase 2

• Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01

  Completed

  Phase 2

• Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01

  Completed

  Phase 2, Phase 3

• Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29

  Active, not recruiting

  Phase 3

• Phase 2 Study of ONC201 in Neuroendocrine Tumors Start of enrollment: 2017 Aug 02

  Completed

  Phase 2

• Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC Start of enrollment: 2020 Jan 13

  Recruiting

  Phase 2

  Roles: Contact, Principal Investigator

• Join now to see all